Journal
ALLERGY
Volume 68, Issue 6, Pages 803-808Publisher
WILEY
DOI: 10.1111/all.12158
Keywords
allergens; immunotherapy; peanut allergens; peanut allergy
Categories
Funding
- NIH-NIAID [U19AI066738, U01AI066560]
- National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) [UL1 1TR000067, UL1 TR000424]
Ask authors/readers for more resources
Background Immunotherapy for peanut allergy may be limited by the risk of adverse reactions. Objective To investigate the safety and immunologic effects of a vaccine containing modified peanut proteins. Methods This was a phase 1 trial of EMP-123, a rectally administered suspension of recombinant Ara h 1, Ara h 2, and Ara h 3, modified by amino acid substitutions at major IgE-binding epitopes, encapsulated in heat/phenol-killed E.coli. Five healthy adults were treated with 4 weekly escalating doses after which 10 peanut-allergic adults received weekly dose escalations over 10weeks from 10 mcg to 3063 mcg, followed by three biweekly doses of 3063 mcg. Results There were no significant adverse effects in the healthy volunteers. Of the 10 peanut-allergic subjects [4 with intermittent asthma, median peanut IgE 33.3 kUA/l (7.2120.2), and median peanut skin prick test wheal 11.3mm (6.518)]; four experienced no symptoms; one had mild rectal symptoms; and the remaining five experienced adverse reactions preventing completion of dosing. Two were categorized as mild, but the remaining three were more severe, including one moderate reaction and two anaphylactic reactions. Baseline peanut IgE was significantly higher in the five reactive subjects (median 82.4 vs 17.2 kUA/l, P=0.032), as was baseline anti-Ara h 2 IgE (43.3 versus 8.3, P=0.036). Peanut skin test titration and basophil activation (at a single dilution) were significantly reduced after treatment, but no significant changes were detected for total IgE, peanut IgE, or peanut IgG4. Conclusions Rectal administration of EMP-123 resulted in frequent adverse reactions, including severe allergic reactions in 20%.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available